A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: Phase II)

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 7, 2006, Pages 840-845

  Carracosa, J M ^a   Pujol, R ^b   Dauden E ^c   Hernanz Hermosa, J M ^d   Bordas, X ^e   Smandia, J A ^f   Ferrandiz C ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f Hospital Creu Roja   (Spain)

Author keywords

Costs; Economics; Psoriasis; Therapy

Indexed keywords

CALCIPOTRIOL; CORTICOSTEROID; VITAMIN D DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST OF ILLNESS; DEMOGRAPHY; DISEASE SEVERITY; DRUG COST; FEMALE; HEALTH CARE; HEALTH CARE COST; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; SCHOOL CHILD; SPAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSORIASIS; SPAIN;

EID: 33746319412     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01659.x     Document Type: Article

References (21)

1. Finlay AY. Psoriasis from the patient's point of view. Arch Dermatol 2001; 137: 352-353.
2. Braathen LR. Cost of caring for hospital-based patients in dermatology in Europe. J Eur Acad Dermatol Venereol 2001; 15: 292.
3. Dehkharghani S, Bible J, Chen JG et al. The economic burden of skin disease in the United States. J Am Acad Dermatol 2003; 48: 592-599.
4. Galadari I, Rigel E, Lebwohl M. The cost of psoriasis treatment. J Eur Acad Dermatol Venereol 2001; 15: 320-324.
5. Vademecum International. Available online at: http://www.vademecum.medicom.es, 2004.
6. Precios y Costes Laborales. Boletín Mensual de Estadística, May 2004 (149), 21-32 Available online at: http://www.ine.es, 2004.
7. Ferrandiz C, Bordas X, García-Patos V et al. Prevalence of psoriasis in Spain. J Eur Acad Dermatol Venereol 2001; 15: 20-23.
8. Finzi AF, Mantovani LG, Belisari A. The expenses of hospital-related care of patients with psoriasis in Italy based on the AISP study. J Eur Acad Dermatol Venereol 2001; 15: 320-324.
9. Sander HM, Morris LF, Phillips CM et al. The annual expenses of psoriasis. J Am Acad Dermatol 1993; 3: 422-425.
10. Krueger GG, Bergstresser PR, Lowe NJ et al. Psoriasis. J Am Acad Dermatol 1984; 11: 937-947.
11. Kraning KK, Odland GF. Research needs in 11 major areas in dermatology. I. Psoriasis. J Invest Dermatol 1979; 73: 402-413.
12. Javitz HS, Ward MM, Farber E et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002; 46: 850-860.
13. Jenner N, Campbell J, Plunkett A, Marks R. Cost of psoriasis: A study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol 2002; 43: 255-261.
14. Marchett A, Lapensee K, An P. A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: A US study. Clin Ther 1998; 20: 851-869.
15. Newton GD, Pray WS, Popovich NG. New OTC drugs and devices 2003: A selective review. J Am Pharm Assoc (Wash DC) 2004; 44: 211-225.
16. Stern RS. PUVA follow-up study. Inpatient hospital care for psoriasis: A vanishing practice in the United States. J Am Acad Dermatol 2003; 49: 445-450.
17. Feldman SR, Fleischer AB, Reboussin DM et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37: 564-569.
18. Galdari I, Rigel E, Lebwohl M. The cost of psoriasis treatment. J Eur Acad Dermatol Venereol 2001; 15: 290-291.
19. Opmeer BC, Heydendael VM, De Borgie CA et al. Costs of treatment in patients with moderate to severe plaque psoriasis. Economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol 2004; 140: 685-690.
20. Levin C, Maibach H. Exploration of 'alternative' and 'natural' drugs in dermatology. Arch Dermatol. 2002; 138: 207-211.
21. Finlay AY. Skin disease disability: Measuring its magnitude. Keio J Med 1998; 47: 131-134.